Filing Flows › Comparisons › RGEN vs RVMD
Repligen vs Revolution Medicines: RGEN and RVMD compared
Repligen is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $198M for Revolution Medicines (Q3 2026). Repligen is more profitable, with an operating margin of -14.1% against -188.9%.
Where the money goes: RGEN and RVMD
Repligen (RGEN) · Q3 2026
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart follows the revenue to costs, profit and cash.
Revolution Medicines (RVMD) · Q3 2026
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
| Repligen (RGEN) | Revolution Medicines (RVMD) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $209M | $198M |
| Revenue growth, Y/Y | +11% | — |
| Operating margin | -14.1% | -188.9% |
| Net earnings | −$38.4M | −$407M |
| Net margin | -18.4% | -206.2% |
| Operating cash flow | $43.1M | −$416M |
| Free cash flow | $38.2M | — |
| Market value | $9.9B | — |
| Analysts’ mean target | $203.45 | — |
Where the revenue comes from
Repligen
- Product: $209M (100%)
- Royalty and other revenue: $44K (0%)
Questions
Which is bigger, Repligen or Revolution Medicines?
Repligen is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $198M for Revolution Medicines (Q3 2026).
Is Repligen or Revolution Medicines growing faster?
Repligen is more profitable, with an operating margin of -14.1% against -188.9%.
More: Repligen earnings · how Repligen makes money · Revolution Medicines earnings · how Revolution Medicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.